Stoke Therapeutics Inc
STOKHealthcare|Biotechnology|USA
$31.38
-1.47 (-4.47%)
Tangible Book
$6.34
Upcoming Data Readouts (2)
Mar 2027
Est. completion
P3Dravet Syndrome
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125n=170
Mar 2029
Est. completion
P2Dravet Syndrome
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
NCT04740476n=60